Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET
Fulcrum Therapeutics (FULC) will release its Q3 2021 financial results on November 4, 2021, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET to discuss results and recent corporate developments. Fulcrum's focus is on patients with genetically defined rare diseases, with notable advancements including losmapimod in Phase 2 trials for facioscapulohumeral muscular dystrophy and FTX-6058 in Phase 1 trials for sickle cell disease and beta-thalassemia.
- Advancement of losmapimod to Phase 2 for FSHD treatment.
- FTX-6058 has entered Phase 1 development for sickle cell disease and beta-thalassemia.
- None.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2021 financial results will be released on Thursday, November 4, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: 800-527-6973
International Dial-in Number: 470-495-9162
Conference ID: 7525705
Replay Dial-in Number: 855-859-2056
Replay International Dial-in Number: 404-537-3406
Conference ID: 7525705
An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. Fulcrum has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
Please visit www.fulcrumtx.com.
Contact:
Naomi Aoki
Senior Vice President,
Corporate Communications and Investor Relations
naoki@fulcrumtx.com
FAQ
When will Fulcrum Therapeutics release its Q3 2021 financial results?
What time is the conference call for Fulcrum Therapeutics Q3 2021 results?
What are the main developments for Fulcrum Therapeutics?
